Posts by: Daniela Semedo, PhD

Daniela Semedo, PhD

Daniela holds a PhD in Clinical Psychology from The University of Edinburgh, United Kingdom, a MSc in Health Psychology and a BSc in Clinical Psychology. Her work has been focused on vulnerability to psychopathology and early identification and intervention in psychosis.

November 2, 2015November 5, 2015

Mallinckrodt’s INOmax Granted Approved In Japan and Australia For Pulmonary Hypertension In Conjunction With Heart Surgery

News, Pulmonary Hypertension

Biopharmaceutical company Mallinckrodt plc., recently announced that INOmax® (nitric oxide) for inhalation has been approved in Japan for pulmonary hypertension associated with heart surgery. INOmax is a vasodilator that improves ventilation/perfusion (V/Q) ... Read more

October 30, 2015November 5, 2015

OrPro’s Cystic Fibrosis Treatment Theradux Receives US Patent

Cystic Fibrosis, News

OrPro Therapeutics, Inc. a company developing Theradux (ORP-100), a new inhaled treatment designed to treat cystic fibrosis (CF) and other obstructive diseases characterized by thickened, stiff and adhesive mucus, recently announced ... Read more

October 30, 2015November 9, 2015

FDA Approves Novartis’ Utibron Neohaler Dual Bronchodilator for COPD

COPD, News

Novartis announced that the FDA recently approved the dual combined bronchodilator Utibron™ Neohaler® (indacaterol/glycopyrrolate), an inhalation powder for long-term maintenance therapy of airflow obstruction in patients with chronic obstructive pulmonary disease (COPD), including ... Read more

October 29, 2015November 5, 2015

Boehringer Reports Efficacy of OFEV in Idiopathic Pulmonary Fibrosis Studies

Idiopathic Pulmonary Fibrosis, News

Boehringer Ingelheim Pharmaceuticals, Inc., recently presented post-hoc analyses from the Phase III INPULSIS™ clinical trials at the American College of Chest Physicians Annual Meeting (CHEST 2015) in Montreal, Canada. Results ... Read more

October 29, 2015October 29, 2015

Merck’s NSCLC Drug Keytruda Outperforms Established Chemotherapy Drug

Lung Cancer, News

Merck recently announced topline data from the KEYNOTE-010 clinical trial assessing pembrolizumab as a treatment for patients with advanced non-small-cell lung cancer (NSCLC), determining that the study met its initial endpoint. Pembrolizumab (formerly MK-3475 and lambrolizumab, ... Read more

October 26, 2015November 5, 2015

GSK’s Volibris (Ambrisetan) Indication Expanded for PAH in Europe After CHMP Positive Opinion

News, Pulmonary Hypertension

GSK, a world leading research-based pharmaceutical and health care company, recently announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has released a ... Read more

October 23, 2015November 5, 2015

New PAH Trial Results for Selexipag Therapy to Be Presented by Actelion at CHEST 2015

News, Pulmonary Hypertension

Actelion, Ltd., a biopharmaceutical company headquartered in Switzerland and focused on the discovery, development, and commercialization of innovative treatments for unmet medical needs, recently announced that additional important results from its pivotal Phase ... Read more

October 22, 2015October 22, 2015

Synta Ceases Phase 3 GALAXY-2 Trial in Patients with Advanced Non-small Cell Lung Adenocarcinoma

Lung Cancer, News

Synta Pharmaceuticals Corp., a biopharmaceutical company focused on research, development and commercialization of novel oncology medicines, recently announced that the company has decided to cease its Phase 3 GALAXY-2 trial of docetaxel ... Read more

October 15, 2015November 9, 2015

Verona Pharma Announces First Patient Dosed in Phase IIa Study of RPL554 for COPD

COPD, News

Verona Pharma plc, a company with a focus on first-in-class drugs for the treatment of respiratory diseases, recently announced that the first patient was dosed in its Phase IIa combination ... Read more

October 14, 2015November 5, 2015

European Commission Grants Orphan Drug Designation Status to ProMetic’s PBI-4050 for Idiopathic Pulmonary Fibrosis

Idiopathic Pulmonary Fibrosis, News

ProMetic Life Sciences Inc., a biopharmaceutical company developing bioseparations, plasma-derived therapeutics and small-molecule drugs, recently announced that the European Commission has granted orphan drug designation status to the company’s drug candidate ... Read more